William Stager Selected Research

lixisenatide

1/2020	Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data.
1/2019	Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.
1/2019	Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
11/2018	Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.
12/2017	Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
11/2017	Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.
10/2017	Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
1/2017	Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.
9/2016	Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William Stager Research Topics

Disease

9	Type 2 Diabetes Mellitus (MODY) 01/2020 - 09/2016
3	Hypoglycemia (Reactive Hypoglycemia) 01/2020 - 01/2019
3	Weight Gain 01/2019 - 12/2017
2	Body Weight (Weight, Body) 01/2019 - 10/2017
2	Vomiting 11/2017 - 01/2017
2	Nausea 11/2017 - 01/2017
1	Obesity 10/2017

Drug/Important Bio-Agent (IBA)

9	lixisenatideIBA 01/2020 - 09/2016
6	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 09/2016
5	Insulin Glargine (Lantus)FDA Link 01/2019 - 10/2017
3	Insulin (Novolin)FDA Link 01/2020 - 10/2017
2	Glucagon-Like Peptide-1 ReceptorIBA 01/2020 - 11/2017
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2019 - 09/2016
1	Blood Glucose (Blood Sugar)IBA 01/2019
1	antineoplaston A10 (A 10)IBA 11/2017
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2017
1	Glucagon (Glukagon)FDA Link 09/2016

Therapy/Procedure

2	Glycemic Control 01/2020 - 01/2019
2	Therapeutics 12/2017 - 01/2017